Perceptive Advisors, founded by Joseph Edelman and headquartered in New York, specializes in healthcare sector investments. The firm maintains a global focus, investing in both public and private companies engaged in biotechnology products, pharmaceuticals, medical devices, and diagnostics. Perceptive Advisors is equipped to engage in various stages of investment, including early and late-stage ventures, crossover rounds, leading IPOs, and public follow-on financings, showcasing its robust capabilities within the healthcare investment landscape.
Joseph Edelman is the founder and Chief Executive Officer of Perceptive Advisors LLC, a prominent hedge fund based in New York City that specializes in biotechnology stocks. Established in 1999, Perceptive Advisors aims to advance the life sciences industry by identifying and investing in promising technologies that can positively impact healthcare. Joe began his academic journey by earning a Bachelor of Arts in Psychology with magna cum laude honors from the University of California, San Diego. His initial pursuit of a graduate degree in Psychopharmacology led him to pivot towards business, ultimately earning a Master of Business Administration from the Leonard N. Stern School of Business at New York University. Combining his background in psychology with his expertise in investing and portfolio management, Joe has assembled a team at Perceptive Advisors comprising medical doctors and PhDs. Together, they focus on uncovering trends, innovative technologies, and undervalued assets within the life sciences sector to generate returns for investors and foster advancements in healthcare. In addition to his professional accomplishments, Joe is deeply involved in philanthropic endeavors aimed at enhancing the well-being of individuals and communities. He serves on the Board of Trustees at Brown University and holds a position on the Board of Directors at the New York Genome Center and Athira Pharma.
Perceptive Advisors manages discretionary assets totaling $9,715,749,804 as of their latest Form ADV dated April 2024. Specializing in healthcare sector investments, Perceptive Advisors serves 29 clients and reported $5,757,958,145 in managed 13F securities for Q1 2024. The firm's top 10 holdings represent 39.99% of its portfolio, with Cerevel Therapeutics Holdings, Inc. as its largest holding, with 10,794,876 shares held.
| Fund Name: | Perceptive Advisors |
| Manager | Joseph Edelman |
| Portfolio Value | $4,726,735,830 |
| Change This QTR | +1.14% |
| No. | Security | Ticker | Shares | Value | Activity | % Port | History |
|---|---|---|---|---|---|---|---|
| 1. | ACLX | 3,888,669 | $324,742,748 | -1% | 6.87% | ||
| 2. | NUVL | 2,979,235 | $304,775,741 | +17% | 6.44% | ||
| 3. | FOLD | 28,057,456 | $299,653,630 | 6.33% | |||
| 4. | IOVA | 26,617,709 | $249,940,287 | +3% | 5.28% | ||
| 5. | PCVX | 2,027,608 | $231,694,766 | +9% | 4.9% |
| Symbol | Company | Filed By | Filing Date | Filing |
|---|---|---|---|---|
| 2024-06-06 | ||||
| 2024-05-13 | ||||
| 2024-05-01 | ||||
| 2024-04-17 | ||||
| 2024-04-17 |
